Artivion/$AORT
1D1W1MYTD1Y5YMAX
Capital at risk
About Artivion
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
- Ticker
- $AORT
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 1,800
- Headquarters
- Kennesaw, United States
- Website
- artivion.com
Artivion Metrics
BasicAdvanced
$1.2B
-
-$0.07
1.25
-
Price and volume
Market cap
$1.2B
Beta
1.25
52-week high
$48.25
52-week low
$19.16
Average daily volume
699K
Financial strength
Current ratio
3.473
Quick ratio
1.759
Long term debt to equity
90.229
Total debt to equity
91.558
Interest coverage (TTM)
1.38%
Profitability
EBITDA (TTM)
58.206
Gross margin (TTM)
64.37%
Net profit margin (TTM)
-0.67%
Operating margin (TTM)
7.14%
Effective tax rate (TTM)
241.74%
Revenue per employee (TTM)
$260,000
Management effectiveness
Return on assets (TTM)
2.20%
Return on equity (TTM)
-0.73%
Valuation
Price to revenue (TTM)
2.595
Price to book
2.79
Price to tangible book (TTM)
-9.71
Price to free cash flow (TTM)
-71.32
Free cash flow yield (TTM)
-1.40%
Free cash flow per share (TTM)
-0.359
Growth
Revenue change (TTM)
16.40%
Earnings per share change (TTM)
-84.21%
3-year revenue growth (CAGR)
12.77%
10-year revenue growth (CAGR)
10.96%
3-year earnings per share growth (CAGR)
-54.44%
10-year earnings per share growth (CAGR)
-14.33%
What the Analysts think about Artivion
Analyst ratings (Buy, Hold, Sell) for Artivion stock.
Analyst projections of the future price of Artivion stock.
Bulls say / Bears say
Artivion delivered 12% year-over-year constant currency revenue growth to $116.3 million in Q1 2026, beating analyst expectations and reflecting broad demand for its aortic-centric solutions. (Reuters)
The company’s adjusted EBITDA surged 26% to $22.1 million in Q1 2026 versus the prior year, driven by operational leverage and a favorable product mix. (Reuters)
Artivion’s On-X mechanical heart valve posted 17% constant currency growth in Q1 2026, supported by recent low-INR label approvals and compelling clinical data demonstrating reduced bleeding events. (Reuters)
Management lowered full-year 2026 revenue guidance to $480–496 million (7–11% growth) from prior expectations due to softer-than-anticipated AMDS set sales in the U.S. and weaker international stent graft performance. (Reuters)
Despite an improvement, free cash flow remained negative $6.8 million in Q1 2026, highlighting continued capital intensity as the company expands manufacturing and clinical infrastructure. (Reuters)
Ongoing supply chain disruptions, particularly in the Middle East, impeded international stent graft sales in Q1 2026 and pose a risk to near-term revenue targets. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 14 Aug 2026.
Artivion Financial Performance
Revenues and expenses
Artivion Earnings Performance
Company profitability
Upcoming events
No upcoming events
Artivion News
AllArticlesVideos
Funds containing Artivion
AllUSDGBPEUR
Fund name | Fund size | $AORT weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.06% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.06% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.04% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.